UCB sells to Adams Respiratory Therapeutics Delsym cough surpressants
UCB S.A. announces that it has reached an agreement with Adams Respiratory Therapeutics Inc. to sell Delsym® (dextromethorphan polistirex), an over-the-counter (OTC) 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology.
The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.